Xpert® CT/NG
90-minute detection and differentiation of Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG)
Sign in or create a MyCepheid account to add items to cart
Test pack size(s)
product image
10 Tests
Unit price
Product is not available for purchase in your region.
Collection devices
product image
Swab Specimen Collection Kit (Pack of 50)
Unit price
Product is not available for purchase in your region.
product image
Urine Collection Kit (Pack of 50)
Unit price
Product is not available for purchase in your region.
Error adding items to cart. If this error persists, please contact Digital Support

The Need

Trichomoniasis, chlamydia, and gonorrhea are the three most prevalent, treatable STDs in the U.S. If left untreated, complications can include infertility, pelvic inflammatory disease, pregnancy complications, and increased risk of HIV acquisition.1

CDC recommends:1
  • Annual CT/NG screening of all sexually active women under 25
  • Screening of other at-risk individuals including MSM*
  • Testing for chlamydia, gonorrhea, & trichomoniasis using NAATs^ (PCR)
  • Same-day testing and treatment
1Workowski KA, et al. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep. 2015 Jun 5;64(RR-03):1-137
*MSM — men who have sex with men
^NAAT — nucleic acid amplification test

The Solution

Accurate on-demand PCR results are ready when you need them
  • On-demand and in-visit results reduce patient call-backs, overtreatment, undertreatment and patients lost to follow-up
  • Patient collected specimens can create operational efficiencies
  • Same patient sample can be utilized for all tests

The Impact

Provide fast patient results to:
  • Lessen patient anxiety with immediate results
  • Improve patient satisfaction
  • Prevent disease spread in the community
  • Reduce unnecessary use of antibiotics

Frequently Asked Questions

The Xpert® CT/NG test is a qualitative in vitro real-time PCR test for the automated detection and differentiation of genomic DNA from Chlamydia trachomatis (CT) and/or Neisseria gonorrhoeae (NG) to aid in the diagnosis of chlamydial and gonorrheal disease in the urogenital tract and extragenital sites (pharynx and rectum). (1)

The test may be used with the following specimens from asymptomatic and symptomatic individuals: female and male urine, patient-collected vaginal swabs (collected in a clinical setting), clinician-collected endocervical swabs, and female and male pharyngeal and rectal swabs. (1)

Chlamydia trachomatis (CT) are Gram-negative, non-motile, bacteria that exist as obligate intracellular parasites of eukaryotic cells due to their inability to synthesize ATP. The CT species is comprised of at least fifteen serovars that can cause disease in humans; serovars D through K are the major cause of genital chlamydial infections in men and women. (1)

Left untreated, CT can cause non-gonococcal urethritis, epididymitis, proctitis, cervicitis, and acute salpingitis. In women, untreated CT can lead to pelvic inflammatory disease (PID) in more than 40% of the infected population and render up to 20% infertile. PID can manifest as endometritis, salpingitis, pelvic peritonitis, and tubo-ovarian abscesses. (1)

Neisseria gonorrhoeae (NG) are non-motile, Gram-negative diplococci, and the causative agent of gonorrheal disease. Gonorrhea is the second most reported bacterial sexually transmitted disease (STD). (1)

With rapid laboratory results, treatment delays are reduced, resulting in fewer complications, less onward transmission of STDs, less time spent tracking and verifying treatment for those who fail to return after a positive test result, and more prudent use of antimicrobial agents based on less empiric treatment. (2)


  1. Cepheid. Xpert CT/NG Package Insert. Accessed Dec. 18, 2023. https://www.cepheid.com/en-USntent/dam/www-cepheid-com/documents/package-insert-files/Xpert-CTNG-US-ENGLISH-Package-Insert-301-0234--Rev-K.pdf
  2. Barrow RY, Ahmed F, Bolan GA, Workowski KA. Recommendations for Providing Quality Sexually Transmitted Diseases Clinical Services, 2020. MMWR Recomm Rep 2020;68(No. RR-5):1–20. DOI: http://dx.doi.org/10.15585/mmwr.rr6805a1